US2009281033A1PendingUtilityA1

Control of radiation injury

64
Assignee: BIOTEMPT BVPriority: Mar 7, 2006Filed: Oct 24, 2008Published: Nov 12, 2009
Est. expiryMar 7, 2026(expired)· nominal 20-yr term from priority
A61P 39/00A61P 43/00A61P 1/00A61K 38/06A61K 38/07A61K 9/0019A61K 38/08
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to the field of drug development against acute radiation injury caused by exposure to high-energy electromagnetic waves (X-rays, gamma rays) or particles (alpha particles, beta particles, neutrons). To date, there is no effective drug to ameliorate radiation injury after accidental exposure to ionizing irradiation. The invention provides a method of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids. Furthermore, the invention provides use of a peptide, or functional analogue or derivative thereof, of smaller than 30 amino acids for the production of a pharmaceutical composition for the treatment of a subject suffering from or believed to be suffering from radiation injury. In particular, the invention provides anti-radiation peptides having a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with said peptide at 72 hours after WBI and, testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of said peptide at 72 hours after WBI and wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals.

Claims

exact text as granted — not AI-modified
1 .- 14 . (canceled) 
     
     
         15 . An autoinjector for administering a parenteral composition, the improvement comprising, including in said autoinjector, adapted for injection, means for treating or preventing radiation injury. 
     
     
         16 . The autoinjector of  claim 15 , wherein the means for treating or preventing radiation injury comprises a peptide, or functional analogue or derivative thereof, of smaller than thirty (30) amino acids. 
     
     
         17 . The autoinjector of  claim 16  wherein the means for treating or preventing radiation injury comprises a peptide, the peptide being smaller than fifteen (15) amino acids. 
     
     
         18 . The autoinjector of  claim 17  wherein the peptide is smaller than seven (7) amino acids. 
     
     
         19 . The autoinjector of  claim 18  wherein the peptide consists of from two (2) to six (6) amino acids. 
     
     
         20 . The autoinjector of  claim 19 , wherein the peptide consists of from three (3) to five (5) amino acids. 
     
     
         21 . The autoinjector of  claim 20  wherein the peptide consists of four (4) amino acids. 
     
     
         22 . The autoinjector of  claim 16 , wherein the radiation injury comprises acute radiation injury. 
     
     
         23 . The autoinjector of  claim 16 , wherein said radiation injury comprises damage of the lining of the intestinal tract of said subject, the so-called gastrointestinal syndrome. 
     
     
         24 . The autoinjector of  claim 16 , wherein the peptide has a dose reduction factor (DRF) against acute gamma irradiation of at least 1.10, said DRF determinable by
 a. testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a test group of mice treated with the peptide at 72 hours after WBI and,   b. testing which dose of radiation results in 50% mortality at 30 days (LD50/30) after whole body radiation (WBI) in a control group of mice treated only with the vehicle of the peptide at 72 hours after WBI and,   c. wherein the DRF is calculated by dividing the LD50/30 of the peptide-treated animals by the LD50/30 of the vehicle-treated animals.   
     
     
         25 . The autoinjector of  claim 24  wherein the peptide has a DRF of at least 1.20 or at least 1.25. 
     
     
         26 . The autoinjector of  claim 16 , wherein said radiation injury is irradiation injury. 
     
     
         27 . The autoinjector of  claim 16 , wherein said radiation is emitted by radioactive substances.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.